Weekly Ratings, Targets, Forecast Changes – 19-05-23

Weekly Reports | May 22 2023

By Mark Woodruff


The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquarie, Morgan Stanley, Morgans, Ord Minnett, Shaw and Partners and UBS.

For the purpose of broker rating correlation, Outperform and Overweight ratings are grouped as Buy, Neutral is grouped with Hold and Underperform and Underweight are grouped as Sell to provide a Buy/Hold/Sell (B/H/S) ratio.

Ratings, consensus target price and forecast earnings tables are published at the bottom of this report.


Period: Monday May 15 to Friday May 19, 2023
Total Upgrades: 10
Total Downgrades: 11
Net Ratings Breakdown: Buy 57.63%; Hold 33.74%; Sell 8.63%

For the week ending Friday May 19 there were ten upgrades and eleven downgrades to ASX-listed companies by brokers in the FNArena database.

A review of the target price and earnings tables below shows a positive week for accounting software firm Xero and Avita Medical, while agricultural names Elders and Incitec Pivot experienced negative reviews by analysts.

Following FY23 results that exceeded expectations, Xero appeared atop the tables for both the largest percentage increase in average target price and forecast earnings by the six covering brokers in the database. 

Morgan Stanley now has the highest target price of the six after an increase to $125 from $100. It’s felt actions by the new CEO have been decisive and make strategic sense, which in turn has started to de-risk the outlook for equity holders. 

In particular, the broker praised management’s new commitment to further cost reductions. The technical team's efficiency program is expected to finish by July, and, as a result, Citi envisaged upside risk to margin guidance based on current top-line trends.

After an around 20% share price rally in the last few months, Morgans lowered its rating to Hold from Add, while also raising its target to $101 from $97.

One of Xero’s key performance metrics is the “rule of 40”, which tries to strike a balance between growth and profitability by targeting the revenue growth and free cash flow margin percentage to total at least 40%.

Ord Minnett estimated the total has hovered around 30% in the last five years and will remain at a similar level for the next decade. A Sell rating is retained though the target was increased by 10% to $66. 

Avita Medical came second behind Xero for percentage increase in target price and fifth on the list for increase in average forecast earnings by brokers after achieving March quarterly guidance and maintaining full year revenue guidance.

For broker opinions on the result and some potentially exciting upcoming share price catalysts please refer to: https://www.fnarena.com/index.php/2023/05/17/avita-medical-preps-for-enlarged-us-opportunity/

On the negative side of the ledger, Elders topped the list for the largest percentage decrease in average target price (-25%) and forecast earnings, after five covering brokers in the database updated research.

First half results reflected a volatile agricultural backdrop impacted by weaker livestock trading conditions, softer crop input prices and unseasonably wet weather, explained Macquarie, which downgraded its rating to Neutral from Outperform and lowered its target to $7.77 from $14.35.

The earnings margin fell to 5.0% from 8.8% and the return on capital (ROC) declined to 16.9% from 27.8% in the previous corresponding period.

While FY23 earnings guidance was a -5% miss against the consensus forecast, it met the prior forecast by Neutral-rated UBS, suggesting an uptick in the September half. Shaw and Partners (Buy) felt achieving this guidance will be assisted by the positive outlook for the Australian winter crop.

Incitec Pivot was second behind Elders for percentage fall in average target price last week and fourth on the earnings downgrade table.

While the company’s first half results materially missed consensus expectations, largely due to a significant fall in fertiliser prices over recent months, some brokers see value on offer. More details are available from: https://www.fnarena.com/index.php/2023/05/18/incitec-pivot-misses-expectations-demerger-pending

NextDC was second on the table for lower forecast earnings after Ord Minnett updated its research for a $618m equity raising at $10.80 per share, which was announced in the previous week. 

Funds raised will be used for new data centre developments in Kuala Lumpur and Auckland, together with the accelerated data hall fit-out in the third Sydney centre. Management is also evaluating Singapore and Tokyo as potential markets.

Returning to positive earnings upgrades last week, the SaaS industry group was well represented with increased forecasts for Serko, Tyro Payments and Appen.

Following FY23 results, Ord Minnett suggested the market has overlooked the likes of expense management company Serko (that may evolve into a serious player in its industry) in taking a broadly negative approach to long-duration growth assets that have been generating negative free cash flow.

The loss for the period was smaller than expected and the broker forecast Serko will be generating material free cashflow of $35m by FY26.

When contemplating revenue growth of 40% and falling cash burn, Buy-rated Citi suggested the current valuation was undemanding and raised its target to $4.10 from $3.60, while Morgans upgraded its rating to Outperform from Neutral on what was considered a quality beat for the Booking.com joint venture.

Booking.com offers and promotes Serko's travel booking and expense management tool Zeno to its business traveller customers, while Booking.com content is displayed on Zeno.

Macquarie raised its earnings forecast and upgraded its rating for Tyro Payments to Outperform from Neutral following a third upgrade to FY23 guidance, which eased concerns around management’s ability to manage a weaker consumer demand environment.

Brokers also raised earnings forecasts for Appen, which raised $600m in equity to provide balance sheet flexibility and help fund one-off costs associated with its previously announced cost reduction program.

Bell Potter upgraded its rating to Hold from Sell, noting no requirement for the company to take on debt or do another capital raising for at least the next three years.

Total Buy recommendations in the database comprise 57.63% of the total, versus 33.74% on Neutral/Hold, while Sell ratings account for the remaining 8.63%.


APPEN LIMITED ((APX)) Upgrade to Hold from Sell by Bell Potter .B/H/S: 0/1/3

Bell Potter updates forecasts to allow for the capital raising that Appen announced. There are no changes to underlying revenue and EBITDA forecasts.

Modest reductions in forecast losses are made and the broker has removed the borrowings it previously assumed would be drawn in 2023 and 2024.

Bell Potter envisages no need for the company to take on debt or do another capital raising for at least the next three years.

Rating is upgraded to Hold from Sell and the target increases to $2.20 from $2.05. The broker suspects the main negative catalysts have now passed.

AVITA MEDICAL INC ((AVH)) Upgrade to Accumulate from Hold by Ord Minnett .B/H/S: 3/0/0

As the share price of Avita Medical has moved through the trigger level, Ord Minnett upgrades to Accumulate from Hold. Target is $5.60.

BEACH ENERGY LIMITED ((BPT)) Upgrade to Buy from Neutral by Citi .B/H/S: 5/1/1

Following the withdrawal of guidance relating to Waitsia and a -10% decline in the share price since April, Citi assesses the impact is minimal and upgrades to Buy from Neutral.

The broker expects a three-month delay at Waitsia and an extra -$30m in capital expenditure, a smalll dent in valuation.

Meanwhile, Waitsia 2P is being audited and may be updated prior to the August results, providing a catalyst. The Trigg-1 exploration results are also imminent. Target is reduced to $1.65 from $1.70.

CHARTER HALL GROUP ((CHC)) Upgrade to Buy from Neutral by Citi .B/H/S: 4/1/0

Citi upgrades its rating for Charter Hall to Buy from Neutral on evidence of rebounding transaction activity for office assets. Also concerns have been dissipating on further downside to office values and further downside for FY24 consensus estimates.

These FY24 consensus estimates are likely to be supported by a further recovery in transaction activity and a rising CPI (20% of platform income CPI-linked), in the analyst's view.

Citi also sees upside to FY25 earnings on performance fees.

The target falls to $14.60 from $14.80.

INCITEC PIVOT LIMITED ((IPL)) Upgrade to Accumulate from Hold by Ord Minnett .B/H/S: 3/3/0

Despite a negative share price reaction yesterday, first half underlying profit for Incitec Pivot was slightly ahead of Ord Minnett's forecast. The interim dividend of 10cps also exceeded the 9cps anticipated and the broker highlights the attractive yield on offer.

A strong margin performance from Dyno Nobel Americas countered softer-than-expected margins across other segments, explains the analyst. 

Management noted a favourable 2H skew for underlying earnings, without producing any numbers.

Ord Minnett upgrades its rating to Accumulate from Hold and maintains its $3.50 target price.

See also IPL downgrade.

POINTSBET HOLDINGS LIMITED ((PBH)) Upgrade to Buy from Hold by Ord Minnett .B/H/S: 2/0/0

Ord Minnett bypasses an Accumulate rating and upgrades PointsBet Holdings to Buy from Hold after the '"bold call" to sell its US business. The target is also raised to $1.70 from $1.45.

The company has entered into a binding agreement with Fanatics Betting and Gaming to sell its US operations for US$150m though PointsBet will need to fund up to -US$21m up to transaction close after the late-June shareholder meeting.

The net proceeds will likely be distributed to shareholders, along with excess capital, in two tranches, explains the broker. It's felt around $30-40m will remain on the balance sheet of the remaining Australian and Canadian business.

The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE

If you already had your free trial, why not join as a paying subscriber? CLICK HERE